Electrical Stimulation for Nausea, Vomiting and Motion Sickness (PrimaBella and ReliefBand) and Other Selected Indications — CPB 0676 | AETNA Coverage Update

Aetna modified CPB 0676 for electrical stimulation devices used in nausea and vomiting treatment, effective October 8, 2025. Here's what billing teams need to know.

Aetna, a CVS Health company, updated Clinical Policy Bulletin CPB 0676 governing coverage of transcutaneous electrical acupoint stimulation (TEAS) devices — including prescription ReliefBand and PrimaBella — along with auricular neurostimulation and related modalities. The update draws a sharper line between covered and non-covered indications, expands the experimental designation list significantly, and reinforces a hard exclusion on OTC ReliefBand devices as durable medical equipment (DME). If your practice treats oncology, OB/GYN, or surgical patients, this coverage policy directly affects your reimbursement on these devices.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Electrical Stimulation for Nausea, Vomiting and Motion Sickness (PrimaBella and ReliefBand) and Other Selected Indications
Policy Code	CPB 0676
Change Type	Modified
Effective Date	October 8, 2025
Impact Level	Medium — narrow covered indications; large experimental exclusion list adds denial risk
Specialties Affected	Oncology, OB/GYN, anesthesiology, surgery, acupuncture, neurology
Key Action	Audit active orders for TEAS devices against the two covered indications before billing; flag any off-label use for compliance review

---

Aetna Electrical Stimulation Coverage Criteria and Medical Necessity Requirements 2025

Aetna's electrical stimulation coverage policy under CPB 0676 is narrow. Two indications clear the medical necessity bar. Everything else lands in experimental territory.

Covered Indication 1: Post-operative and chemotherapy-induced nausea
Prescription ReliefBand devices are medically necessary for post-operative nausea and chemotherapy-induced nausea — but only when the patient has already failed antiemetics and other conservative therapies. That sequencing matters. If your documentation doesn't show prior treatment failure, expect a claim denial. This isn't a first-line coverage policy; it's a last-resort one.

Covered Indication 2: Hyperemesis gravidarum
Prescription PrimaBella or prescription ReliefBand devices qualify for hyperemesis gravidarum that is unresponsive to conservative medical therapy. Aetna defines conservative therapy here as dietary changes, ginger capsules, and vitamin B6. Your clinical documentation needs to show the patient tried those approaches first.

The word "prescription version" in both covered indications is doing a lot of work. OTC ReliefBand devices — the kind sold directly to consumers for motion sickness — are explicitly excluded. Aetna says they don't meet its definition of durable medical equipment. That's a clean denial every time if you bill a non-prescription device.

While the policy doesn't explicitly call out prior authorization requirements for these devices, Aetna's standard practice for durable medical equipment and prescription devices often involves utilization review. Check the member's specific plan benefits before assuming clean claim passage. If you're not sure how the DME classification applies to your ordering workflow, loop in your compliance officer before submitting.

CPT codes 97813 and 97814 — the acupuncture with electrical stimulation codes — appear in this policy under the experimental grouping for combined magnetic ball compression and TEAS. Don't bill those codes expecting coverage under CPB 0676 unless the indication matches a covered use precisely.

---

Aetna Electrical Stimulation Exclusions and Non-Covered Indications

This is where CPB 0676 gets crowded. Aetna lists more than 25 specific experimental, investigational, or unproven designations. The real issue here is scope creep in clinical practice — providers are ordering TEAS for conditions well outside the two covered indications, and this policy shuts that down explicitly.

The experimental list includes conditions you might assume would qualify given general evidence on neuromodulation:

The length of this experimental list — covering everything from autism to PTSD to hypertension to male infertility — signals that Aetna is pushing back against broad off-label ordering. If your clinicians are prescribing TEAS devices for any of these indications and billing them to Aetna, you have an active claim denial risk.

The OTC device exclusion deserves its own call-out. Aetna's position is that over-the-counter disposable ReliefBand devices for motion sickness don't qualify as DME. That's not a coverage limitation — it's a categorical exclusion. No amount of documentation supports reimbursement for those devices under this policy.

---

Coverage Indications at a Glance

---

Aetna Electrical Stimulation Billing Guidelines and Action Items 2025

The effective date is October 8, 2025. Here's what your billing team needs to do now.

Copy Action Items

If you're unsure whether a specific clinical scenario in your patient population falls inside or outside these billing guidelines, talk to your compliance officer before the October 8, 2025 effective date.

---

CPT, HCPCS, and ICD-10 Codes for Electrical Stimulation Under CPB 0676

Covered CPT Codes (When Medical Necessity Criteria Are Met)

The policy does not assign distinct CPT codes exclusively to covered indications. Coverage is determined by device type (prescription ReliefBand or PrimaBella), clinical indication, and documented treatment failure — not by a specific procedure code. Work with your DME supplier and billing team to identify the appropriate HCPCS device codes for prescription TEAS devices under your MAC's local coverage determination guidance.

Not Covered / Experimental CPT Codes

Note: The full VATS code range (32601–32674) appears in the policy data. Each code in that range carries the same experimental designation for adjunctive TEAS use.

HCPCS Codes

The policy data does not list specific HCPCS codes. Contact your DME billing team to identify applicable HCPCS device codes for prescription ReliefBand and PrimaBella under your regional MAC's guidelines.

Key ICD-10-CM Diagnosis Codes

The policy references 252 ICD-10-CM codes. The full code set is available in the policy source document at Aetna CPB 0676. The most clinically relevant groupings for the two covered indications include codes for:

• Hyperemesis gravidarum (O21.x range)
• Post-operative nausea and vomiting
• Chemotherapy-induced nausea and vomiting

Pull the full ICD-10 list from the source policy to build your covered diagnosis crosswalk. Billing an experimental indication with a covered ICD-10 code won't override the experimental designation — the indication and clinical context still control coverage.

---